President Trump has unveiled a deal to lower costs on two popular obesity drugs. Under the arrangement, drug makers Eli Lilly and Novo Nordisk will expand coverage and reduce prices for their popular weight loss treatments Zepbound and Wegovy. And once new pill versions of the GLP-1 drugs are approved, starting doses will cost 149 dollars a month.